Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The Fast Movers & the Up-and-Comers

On Buzz on the Bullboards, we normally provide the Stockhouse Community with a snapshot of recent Bullboard activity, often accompanied by an Investor Pulse Poll – providing you with information on current sentiment. It has been generally difficult for energy companie...
Stockhouse Editorial | March 30, 2022 |

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure ...
Streetwise Reports | November 15, 2019 |

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

A psilocybin mushroom, also known as a magic mushroom, offers infinite medical and scientific potential…from cognitive flexibility to potentially addressing clinical depression and eating disorders. There’s a lot we still don’t kn...
Dave Jackson | September 18, 2020 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

Getchell Gold Signs Binding Letter Agreement to acquire 1.1m oz Nevada gold resource

Getchell Gold (CSE:GTCH), in our opinion, just became a contender to become a top junior gold exploration player in Nevada. The Toronto-based company announced on October 17, 2019 a binding letter agreement with Canarc Resource Corp. (TSX:CCM) to acquire two Nevada prope...
Richard (Rick) Mills | November 15, 2019 |

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. Biopharmaceutical company Cerecor Inc. (CERC:NASDAQ) , which focuses on development and ...
Streetwise Reports | October 16, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Revolutionizing Mental Health Treatment

(Click to play video.) Cybin Inc. ( NEO: CYBN , NYSE: CYBN , Forum ) is a Toronto-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and...
Featured Submission | August 13, 2021 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

VIDEO: FSD Pharma CEO Raza Bokhari updates investors on ‘HUGE’ news

FSD Pharma Inc. ( CSE: HUGE , OTCQB: FSDDF , Forum ) is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the deve...
Stockhouse Media | October 23, 2019 |
1 2 3 4 5 6 7 8 9